mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because of its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials. Demand for mRNA-based medicine production in lower income countries continues to increase, as do investments in prophylactic and therapeutic indications such as infectious diseases and cancer. We developed a cost-model to compare all modalities such as virus-like particles, viral vectors, and mRNA, which enables decision making on production scale and plant sizing. This poster highlights several aspects of the cost-modelling work, such as the distribution of costs, cost per vaccine dose, and proposes various scenarios to meet forecasted mRNA demand.

Read Now!